Béatrice de Vos
Chief Tech/Sci/R&D Officer chez DMS IMAGING
Profil
Béatrice de Vos is currently the Chief Medical Officer at DMS Imaging SA and a Member at the Belgian College of Pharmaceutical Medicin.
Previously, she served as the Chairman at DMS Imaging SA from 2013 to 2017.
She also held positions as the Regional Director at Wyeth-Ayerst Research from 1992 to 1999, Vice President-Global Medical Affairs at GlaxoSmithKline Biologicals NV from 1999 to 2007, Vice President-Global Medical & Scientific Affairs at Sanofi Pasteur from 2007 to 2010, and Chief Medical Officer at PROMETHERA Biosciences SA from 2011 to 2015.
Dr. de Vos obtained a doctorate degree from the University of Antwerp.
Postes actifs de Béatrice de Vos
| Sociétés | Poste | Début |
|---|---|---|
| DMS IMAGING | Chief Tech/Sci/R&D Officer | - |
| Belgian College of Pharmaceutical Medicin | Corporate Officer/Principal | - |
Anciens postes connus de Béatrice de Vos
| Sociétés | Poste | Fin |
|---|---|---|
| DMS IMAGING | Chairman | 20/03/2017 |
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Chief Tech/Sci/R&D Officer | 01/04/2015 |
Sanofi Pasteur
 Sanofi Pasteur BiotechnologyHealth Technology Sanofi Pasteur SA develops, manufactures and supplies vaccines. It provides vaccines for bacterial and viral diseases, including diphtheria, typhoid fever, and poliomyelitis. The company was founded in 1990 and is headquartered in Lyon, France. | Chief Tech/Sci/R&D Officer | 01/01/2010 |
GlaxoSmithKline Biologicals NV
 GlaxoSmithKline Biologicals NV BiotechnologyHealth Technology GlaxoSmithKline Biologicals SA manufactures vaccines for diseases such as hepatitis, influenza, rubella, and typhoid fever. Its activities include overall strategy, research and development, clinical trials, regulatory matters, production, quality control, marketing, and distribution. The company has partnership with WHO and UNICEF. GlaxoSmithKline Biologicals was founded in 1945 and is headquartered in Rixensart, Belgium. | Chief Tech/Sci/R&D Officer | 01/01/2007 |
| Wyeth-Ayerst Research | Corporate Officer/Principal | 01/01/1999 |
Formation de Béatrice de Vos
| University of Antwerp | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| DMS IMAGING | Health Technology |
| Entreprise privées | 4 |
|---|---|
GlaxoSmithKline Biologicals NV
GlaxoSmithKline Biologicals NV BiotechnologyHealth Technology GlaxoSmithKline Biologicals SA manufactures vaccines for diseases such as hepatitis, influenza, rubella, and typhoid fever. Its activities include overall strategy, research and development, clinical trials, regulatory matters, production, quality control, marketing, and distribution. The company has partnership with WHO and UNICEF. GlaxoSmithKline Biologicals was founded in 1945 and is headquartered in Rixensart, Belgium. | Health Technology |
Sanofi Pasteur
Sanofi Pasteur BiotechnologyHealth Technology Sanofi Pasteur SA develops, manufactures and supplies vaccines. It provides vaccines for bacterial and viral diseases, including diphtheria, typhoid fever, and poliomyelitis. The company was founded in 1990 and is headquartered in Lyon, France. | Health Technology |
| Wyeth-Ayerst Research | |
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Health Technology |
